BioForce Nanosciences Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $341,680 for the third quarter and reporting a significant improvement in total stockholders' equity compared to year-end 2025.

Key Highlights

  • Q3 2026 net loss: The company reported a net loss of $341,680 for the three months ended September 30, 2026, compared to a net loss of $115,915 for the same period in 2025.
  • Nine-month net loss narrowed: For the nine months ended September 30, 2026, the net loss was $205,410, compared to $1,174,153 for the nine months ended September 30, 2025.
  • Total assets grew sharply: Total assets were $2,238,661 at September 30, 2026, up from $786 at December 31, 2025, primarily due to prepaid expenses of $1,972,440 and capitalized land leases of $234,525.
  • Stockholders' equity turned positive: Total stockholders' equity was $1,961,628 at September 30, 2026, compared to a deficit of $618,543 at December 31, 2025.
  • Shares outstanding increased: Common shares outstanding were 38,065,914 as of November 6, 2026, up from 33,521,755 at December 31, 2025.
  • No revenue reported: The company reported zero sales for both the three- and nine-month periods ended September 30, 2026 and 2025.
  • Accumulated deficit: The accumulated deficit stood at $162,617,526 as of September 30, 2026.

BioForce Nanosciences Q3 2026 Financial Position and Operating Results

According to the filing, BioForce Nanosciences Holdings, Inc. reported a net loss of $341,680 for the three months ended September 30, 2026, driven by total operating expenses of $341,680, which included Board of Directors compensation of $33,750 and general and administrative expenses of $307,930. The company recorded no revenue in the quarter, nor in any comparable period disclosed in the filing. The weighted average number of common shares, basic and diluted, was 35,038,096 for the quarter, yielding a net loss per share of $0.01.

For the nine months ended September 30, 2026, the company disclosed a net loss of $205,410, an improvement from the $1,174,153 net loss for the same period in 2025. The improvement was attributed in part to other income items in 2026, including forgiveness of debt of $502,373 and a legal settlement gain of $15,322, partially offset by a loss on liability settlement of $1,361. Total operating expenses for the nine-month period were $721,744, consisting of $283,250 in Board of Directors compensation and $438,494 in general and administrative expenses.

The balance sheet showed a marked change from December 31, 2025. The filing reported total assets of $2,238,661 at September 30, 2026, compared to $786 at year-end 2025. Prepaid expenses of $1,972,440 and capitalized land leases of $234,525 were the primary new asset categories. Cash at the end of the period was $31,696. Total liabilities decreased to $277,033 from $619,329, and stockholders' equity shifted from a deficit of $618,543 to a positive balance of $1,961,628. The company's common stock has a par value of $0.001 per share with 900,000,000 shares authorized. The filing noted no securities are registered under Section 12(b) of the Exchange Act and listed no exchange trading symbol.

What Was Disclosed

BioForce Nanosciences Holdings, Inc. disclosed its unaudited condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, showing no revenue, a Q3 net loss of $341,680, improved nine-month results relative to 2025, and a positive stockholders' equity position of $1,961,628.